title: TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior.
abstract: Treatment options for adenoid cystic carcinoma (ACC) of the salivary gland, a slowly growing tumor with propensity for neuroinvasion and late recurrence, are limited to surgery and radiotherapy. Based on expression analysis performed on clinical specimens of salivary cancers, we identified in ACC expression of the neurotrophin-3 receptor TrkC/NTRK3, neural crest marker SOX10, and other neurologic genes. Here, we characterize TrkC as a novel ACC marker, which was highly expressed in 17 out of 18 ACC primary-tumor specimens, but not in mucoepidermoid salivary carcinomas or head and neck squamous cell carcinoma. Expression of the TrkC ligand NT-3 and Tyr-phosphorylation of TrkC detected in our study suggested the existence of an autocrine signaling loop in ACC with potential therapeutic significance. NT-3 stimulation of U2OS cells with ectopic TrkC expression triggered TrkC phosphorylation and resulted in Ras, Erk 1/2 and Akt activation, as well as VEGFR1 phosphorylation. Without NT-3, TrkC remained unphosphorylated, stimulated accumulation of phospho-p53 and had opposite effects on p-Akt and p-Erk 1/2. NT-3 promoted motility, migration, invasion, soft-agar colony growth and cytoskeleton restructuring in TrkC-expressing U2OS cells. Immunohistochemical analysis demonstrated that TrkC-positive ACC specimens also show high expression of Bcl2, a Trk target regulated via Erk 1/2, in agreement with activation of the TrkC pathway in real tumors. In normal salivary gland tissue, both TrkC and Bcl2 were expressed in myoepithelial cells, suggesting a principal role for this cell lineage in the ACC origin and progression. Sub-micromolar concentrations of a novel potent Trk inhibitor AZD7451 completely blocked TrkC activation and associated tumorigenic behaviors. Pre-clinical studies on ACC tumors engrafted in mice showed efficacy and low toxicity of AZD7451, validating our in vitro data and stimulating more research into its clinical application. In summary, we describe in ACC a previously unrecognized pro-survival neurotrophin signaling pathway and link it with cancer progression.
authors.affiliation: Section of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT 06519-1369, USA. sergey.ivanov@yale.edu
authors.forename: S V
authors.initials: SV
authors.lastname: Ivanov
authors.forename: A
authors.initials: A
authors.lastname: Panaccione
authors.forename: B
authors.initials: B
authors.lastname: Brown
authors.forename: Y
authors.initials: Y
authors.lastname: Guo
authors.forename: C A
authors.initials: CA
authors.lastname: Moskaluk
authors.forename: M J
authors.initials: MJ
authors.lastname: Wick
authors.forename: J L
authors.initials: JL
authors.lastname: Brown
authors.forename: A V
authors.initials: AV
authors.lastname: Ivanova
authors.forename: N
authors.initials: N
authors.lastname: Issaeva
authors.forename: A K
authors.initials: AK
authors.lastname: El-Naggar
authors.forename: W G
authors.initials: WG
authors.lastname: Yarbrough
mesh_terms: D000818:Animals; D003528:Carcinoma, Adenoid Cystic / Q000473:pathology*; D045744:Cell Line, Tumor; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D006801:Humans; D051379:Mice; D009361:Neoplasm Invasiveness; D020933:Neurotrophin 3 / Q000502:physiology*; D010766:Phosphorylation; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D020812:Receptor, trkC / Q000502:physiology*; D051880:Receptors, Notch / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*; D060449:Wnt Signaling Pathway / Q000502:physiology; D018631:ras Proteins / Q000502:physiology
chemical_list: D020933:Neurotrophin 3; D019253:Proto-Oncogene Proteins c-bcl-2; D051880:Receptors, Notch; D020812:Receptor, trkC; D048049:Extracellular Signal-Regulated MAP Kinases; D018631:ras Proteins